Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 474

1.

Cyclin D1 promotes secretion of pro-oncogenic immuno-miRNAs and piRNAs.

Lü J, Zhao Q, Ding X, Guo Y, Li Y, Xu Z, Li S, Wang Z, Shen L, Chen H, Yu Z, Pestell RG.

Clin Sci (Lond). 2020 Mar 27. pii: CS20191318. doi: 10.1042/CS20191318. [Epub ahead of print]

PMID:
32219337
2.

The G protein coupled receptor CCR5 in cancer.

Upadhyaya C, Jiao X, Ashton A, Patel K, Kossenkov AV, Pestell RG.

Adv Cancer Res. 2020;145:29-47. doi: 10.1016/bs.acr.2019.11.001. Epub 2020 Jan 10.

PMID:
32089164
3.

Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme.

Kranjc MK, Novak M, Pestell RG, Lah TT.

Radiol Oncol. 2019 Nov 20;53(4):397-406. doi: 10.2478/raon-2019-0057.

4.

Corrigendum to "Role of UHRF1 in malignancy and its function as a therapeutic target for molecular docking towards the SRA domain" [Int. J. Biochem. Cell Biol. 114 (September 2019) 105558].

Polepalli S, George SM, Valli Sri Vidya R, Rodrigues GS, Ramachandra L, Chandrashekar R, M D, Rao PPN, Pestell RG, Rao M.

Int J Biochem Cell Biol. 2019 Sep;114:105577. doi: 10.1016/j.biocel.2019.105577. Epub 2019 Aug 5.

PMID:
31391149
5.

Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology.

Jiao X, Nawab O, Patel T, Kossenkov AV, Halama N, Jaeger D, Pestell RG.

Cancer Res. 2019 Oct 1;79(19):4801-4807. doi: 10.1158/0008-5472.CAN-19-1167. Epub 2019 Jul 10. Review.

6.

Role of UHRF1 in malignancy and its function as a therapeutic target for molecular docking towards the SRA domain.

Polepalli S, George SM, Valli Sri Vidya R, Rodrigues GS, Ramachandra L, Chandrashekar R, M DN, Rao PPN, Pestell RG, Rao M.

Int J Biochem Cell Biol. 2019 Sep;114:105558. doi: 10.1016/j.biocel.2019.06.006. Epub 2019 Jun 22. Review. Erratum in: Int J Biochem Cell Biol. 2019 Sep;114:105577.

PMID:
31238111
7.

Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.

Di Sante G, Pagé J, Jiao X, Nawab O, Cristofanilli M, Skordalakes E, Pestell RG.

Expert Rev Anticancer Ther. 2019 Jul;19(7):569-587. doi: 10.1080/14737140.2019.1615889. Epub 2019 Jun 20. Review.

8.

Cyclin D1 integrates G9a-mediated histone methylation.

Li Z, Jiao X, Di Sante G, Ertel A, Casimiro MC, Wang M, Katiyar S, Ju X, Klopfenstein DV, Tozeren A, Dampier W, Chepelev I, Jeltsch A, Pestell RG.

Oncogene. 2019 May;38(22):4232-4249. doi: 10.1038/s41388-019-0723-8. Epub 2019 Feb 4.

9.

Dachshund Depletion Disrupts Mammary Gland Development and Diverts the Composition of the Mammary Gland Progenitor Pool.

Jiao X, Li Z, Wang M, Katiyar S, Di Sante G, Farshchian M, South AP, Cocola C, Colombo D, Reinbold R, Zucchi I, Wu K, Tabas I, Spike BT, Pestell RG.

Stem Cell Reports. 2019 Jan 8;12(1):135-151. doi: 10.1016/j.stemcr.2018.11.010. Epub 2018 Dec 13.

10.

An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1.

Zheng Z, Nayak L, Wang W, Yurdagul A Jr, Wang X, Cai B, Lapping S, Ozcan L, Ramakrishnan R, Pestell RG, Jain MK, Tabas I.

Blood. 2019 Feb 14;133(7):743-753. doi: 10.1182/blood-2018-07-864843. Epub 2018 Dec 1.

11.

MAT1 correlates with molecular subtypes and predicts poor survival in breast cancer.

Xu H, Bai X, Yu S, Liu Q, Pestell RG, Wu K.

Chin J Cancer Res. 2018 Jun;30(3):351-363. doi: 10.21147/j.issn.1000-9604.2018.03.07.

12.

Testosterone-mediated activation of androgenic signalling sustains in vitro the transformed and radioresistant phenotype of rhabdomyosarcoma cell lines.

Giannattasio S, Megiorni F, Di Nisio V, Del Fattore A, Fontanella R, Camero S, Antinozzi C, Festuccia C, Gravina GL, Cecconi S, Dominici C, Di Luigi L, Ciccarelli C, De Cesaris P, Riccioli A, Zani BM, Lenzi A, Pestell RG, Filippini A, Crescioli C, Tombolini V, Marampon F.

J Endocrinol Invest. 2019 Feb;42(2):183-197. doi: 10.1007/s40618-018-0900-6. Epub 2018 May 22.

PMID:
29790086
13.

Cyclin D1-mediated microRNA expression signature predicts breast cancer outcome.

Wang G, Gormley M, Qiao J, Zhao Q, Wang M, Di Sante G, Deng S, Dong L, Pestell T, Ju X, Casimiro MC, Addya S, Ertel A, Tozeren A, Li Q, Yu Z, Pestell RG.

Theranostics. 2018 Mar 11;8(8):2251-2263. doi: 10.7150/thno.23877. eCollection 2018.

14.

DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis.

Liu Q, Li A, Yu S, Qin S, Han N, Pestell RG, Han X, Wu K.

J Hematol Oncol. 2018 Apr 10;11(1):53. doi: 10.1186/s13045-018-0597-1.

15.

The dialyzable leukocyte extract TransferonTM inhibits tumor growth and brain metastasis in a murine model of prostate cancer.

Hernández-Esquivel MA, Pérez-Torres A, Romero-Romero L, Reyes-Matute A, Loaiza B, Mellado-Sánchez G, Pavón L, Medina-Rivero E, Pestell RG, Pérez-Tapia SM, Velasco-Velázquez MA.

Biomed Pharmacother. 2018 May;101:938-944. doi: 10.1016/j.biopha.2018.03.012. Epub 2018 Mar 22.

16.

CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.

Jiao X, Velasco-Velázquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, Stucky A, Zhang X, Cristofanilli M, Fatatis A, Gray JW, Zhong JF, Prendergast GC, Pestell RG.

Cancer Res. 2018 Apr 1;78(7):1657-1671. doi: 10.1158/0008-5472.CAN-17-0915. Epub 2018 Jan 22.

17.

Hormone-induced DNA damage response and repair mediated by cyclin D1 in breast and prostate cancer.

Di Sante G, Di Rocco A, Pupo C, Casimiro MC, Pestell RG.

Oncotarget. 2017 Jul 20;8(47):81803-81812. doi: 10.18632/oncotarget.19413. eCollection 2017 Oct 10. Review.

18.

Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth.

Pestell TG, Jiao X, Kumar M, Peck AR, Prisco M, Deng S, Li Z, Ertel A, Casimiro MC, Ju X, Di Rocco A, Di Sante G, Katiyar S, Shupp A, Lisanti MP, Jain P, Wu K, Rui H, Hooper DC, Yu Z, Goldman AR, Speicher DW, Laury-Kleintop L, Pestell RG.

Oncotarget. 2017 Aug 4;8(47):81754-81775. doi: 10.18632/oncotarget.19953. eCollection 2017 Oct 10.

19.

Cytochalasin B-induced membrane vesicles convey angiogenic activity of parental cells.

Gomzikova MO, Zhuravleva MN, Miftakhova RR, Arkhipova SS, Evtugin VG, Khaiboullina SF, Kiyasov AP, Persson JL, Mongan NP, Pestell RG, Rizvanov AA.

Oncotarget. 2017 Jul 31;8(41):70496-70507. doi: 10.18632/oncotarget.19723. eCollection 2017 Sep 19.

20.

Recent advances of bispecific antibodies in solid tumors.

Yu S, Li A, Liu Q, Yuan X, Xu H, Jiao D, Pestell RG, Han X, Wu K.

J Hematol Oncol. 2017 Sep 20;10(1):155. doi: 10.1186/s13045-017-0522-z. Review.

21.

DACH1 suppresses breast cancer as a negative regulator of CD44.

Xu H, Yu S, Yuan X, Xiong J, Kuang D, Pestell RG, Wu K.

Sci Rep. 2017 Jun 28;7(1):4361. doi: 10.1038/s41598-017-04709-2.

22.

Cyclin D1 Restrains Oncogene-Induced Autophagy by Regulating the AMPK-LKB1 Signaling Axis.

Casimiro MC, Di Sante G, Di Rocco A, Loro E, Pupo C, Pestell TG, Bisetto S, Velasco-Velázquez MA, Jiao X, Li Z, Kusminski CM, Seifert EL, Wang C, Ly D, Zheng B, Shen CH, Scherer PE, Pestell RG.

Cancer Res. 2017 Jul 1;77(13):3391-3405. doi: 10.1158/0008-5472.CAN-16-0425. Epub 2017 May 18.

23.

Recent advances of highly selective CDK4/6 inhibitors in breast cancer.

Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell RG, Wu K.

J Hematol Oncol. 2017 Apr 24;10(1):97. doi: 10.1186/s13045-017-0467-2. Review.

24.

Cancer metabolism: a therapeutic perspective.

Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, Lisanti MP.

Nat Rev Clin Oncol. 2017 Feb;14(2):113. doi: 10.1038/nrclinonc.2017.1. Epub 2017 Jan 17. No abstract available.

PMID:
28094266
25.

Biological functions of CDK5 and potential CDK5 targeted clinical treatments.

Shupp A, Casimiro MC, Pestell RG.

Oncotarget. 2017 Mar 7;8(10):17373-17382. doi: 10.18632/oncotarget.14538. Review.

26.

Small RNA zippers lock miRNA molecules and block miRNA function in mammalian cells.

Meng L, Liu C, Lü J, Zhao Q, Deng S, Wang G, Qiao J, Zhang C, Zhen L, Lu Y, Li W, Zhang Y, Pestell RG, Fan H, Chen YH, Liu Z, Yu Z.

Nat Commun. 2017 Jan 3;8:13964. doi: 10.1038/ncomms13964.

27.

Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.

Marampon F, Gravina GL, Ju X, Vetuschi A, Sferra R, Casimiro MC, Pompili S, Festuccia C, Colapietro A, Gaudio E, Di Cesare E, Tombolini V, Pestell RG.

Oncotarget. 2016 Sep 27;7(39):64526. doi: 10.18632/oncotarget.12267. No abstract available.

28.

v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1.

Ju X, Jiao X, Ertel A, Casimiro MC, Di Sante G, Deng S, Li Z, Di Rocco A, Zhan T, Hawkins A, Stoyanova T, Andò S, Fatatis A, Lisanti MP, Gomella LG, Languino LR, Pestell RG.

Cancer Res. 2016 Nov 15;76(22):6723-6734. doi: 10.1158/0008-5472.CAN-15-3327. Epub 2016 Sep 15.

29.

Cancer metabolism: a therapeutic perspective.

Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, Lisanti MP.

Nat Rev Clin Oncol. 2017 Jan;14(1):11-31. doi: 10.1038/nrclinonc.2016.60. Epub 2016 May 4. Review. Erratum in: Nat Rev Clin Oncol. 2017 Feb;14 (2):113.

PMID:
27141887
30.

Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance.

Ozcan L, Ghorpade DS, Zheng Z, de Souza JC, Chen K, Bessler M, Bagloo M, Schrope B, Pestell R, Tabas I.

Cell Rep. 2016 Jun 7;15(10):2214-2225. doi: 10.1016/j.celrep.2016.05.006. Epub 2016 May 26.

31.

Cancer stem cell metabolism.

Peiris-Pagès M, Martinez-Outschoorn UE, Pestell RG, Sotgia F, Lisanti MP.

Breast Cancer Res. 2016 May 24;18(1):55. doi: 10.1186/s13058-016-0712-6. Review.

32.

The retinal determination gene network: from developmental regulator to cancer therapeutic target.

Kong D, Liu Y, Liu Q, Han N, Zhang C, Pestell RG, Wu K, Wu G.

Oncotarget. 2016 Aug 2;7(31):50755-50765. doi: 10.18632/oncotarget.9394. Review.

33.

Time-Lapse Video Microscopy for Assessment of EYFP-Parkin Aggregation as a Marker for Cellular Mitophagy.

Di Sante G, Casimiro MC, Pestell TG, Pestell RG.

J Vis Exp. 2016 May 4;(111). doi: 10.3791/53657.

34.

A direct quantification method for measuring plasma MicroRNAs identified potential biomarkers for detecting metastatic breast cancer.

Zhao Q, Deng S, Wang G, Liu C, Meng L, Qiao S, Shen L, Zhang Y, Lü J, Li W, Zhang Y, Wang M, Pestell RG, Liang C, Yu Z.

Oncotarget. 2016 Apr 19;7(16):21865-74. doi: 10.18632/oncotarget.7990.

35.

Breast Cancer Stem Cell Isolation.

Jiao X, Rizvanov AA, Cristofanilli M, Miftakhova RR, Pestell RG.

Methods Mol Biol. 2016;1406:121-35. doi: 10.1007/978-1-4939-3444-7_10.

PMID:
26820950
36.

The role of CD44 in epithelial-mesenchymal transition and cancer development.

Xu H, Tian Y, Yuan X, Wu H, Liu Q, Pestell RG, Wu K.

Onco Targets Ther. 2015 Dec 16;8:3783-92. doi: 10.2147/OTT.S95470. eCollection 2015. Review.

37.

Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.

Marampon F, Gravina G, Ju X, Vetuschi A, Sferra R, Casimiro M, Pompili S, Festuccia C, Colapietro A, Gaudio E, Di Cesare E, Tombolini V, Pestell RG.

Oncotarget. 2016 Feb 2;7(5):5383-400. doi: 10.18632/oncotarget.6579. Erratum in: Oncotarget. 2016 Sep 27;7(39):64526.

38.

Endogenous Dach1 in cancer.

Wu K, Yuan X, Pestell R.

Oncoscience. 2015 Sep 23;2(10):803-4. eCollection 2015. No abstract available.

39.

Cyclin D1 Promotes Androgen-Dependent DNA Damage Repair in Prostate Cancer Cells.

Casimiro MC, Di Sante G, Ju X, Li Z, Chen K, Crosariol M, Yaman I, Gormley M, Meng H, Lisanti MP, Pestell RG.

Cancer Res. 2016 Jan 15;76(2):329-38. doi: 10.1158/0008-5472.CAN-15-0999. Epub 2015 Nov 18.

40.

Mitochondrial mass and DNA repair in breast cancer stem cells.

Pestell RG, Fatatis A, Jiao X.

Oncotarget. 2015 Nov 17;6(36):38442-3. doi: 10.18632/oncotarget.6305. No abstract available.

41.

Erratum: Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts.

Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, Liu Q, De Angelis T, Riddell LW, Riobo NA, Gleave ME, Zoubeidi A, Pestell RG, Altieri DC, Languino LR.

Oncotarget. 2015 Oct 20;6(32):34038. doi: 10.18632/oncotarget.6187. No abstract available.

42.

FXYD5 is a Marker for Poor Prognosis and a Potential Driver for Metastasis in Ovarian Carcinomas.

Raman P, Purwin T, Pestell R, Tozeren A.

Cancer Inform. 2015 Oct 12;14:113-9. doi: 10.4137/CIN.S30565. eCollection 2015.

43.

EglN2 associates with the NRF1-PGC1α complex and controls mitochondrial function in breast cancer.

Zhang J, Wang C, Chen X, Takada M, Fan C, Zheng X, Wen H, Liu Y, Wang C, Pestell RG, Aird KM, Kaelin WG Jr, Liu XS, Zhang Q.

EMBO J. 2015 Dec 2;34(23):2953-70. doi: 10.15252/embj.201591437. Epub 2015 Oct 22.

44.

Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells.

Lamb R, Ozsvari B, Bonuccelli G, Smith DL, Pestell RG, Martinez-Outschoorn UE, Clarke RB, Sotgia F, Lisanti MP.

Oncotarget. 2015 Sep 8;6(26):21892-905.

45.

Kinase independent oncogenic cyclin D1.

Casimiro MC, Arnold A, Pestell RG.

Aging (Albany NY). 2015 Jul;7(7):455-6. No abstract available.

46.

Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts.

Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, Liu Q, De Angelis T, Riddell LW, Riobo NA, Gleave ME, Zoubeidi A, Pestell RG, Altieri DC, Languino LR.

Oncotarget. 2015 Jun 10;6(16):14318-28. Erratum in: Oncotarget. 2015 Oct 20;6(32):34038.

47.

Kinase-independent role of cyclin D1 in chromosomal instability and mammary tumorigenesis.

Casimiro MC, Di Sante G, Crosariol M, Loro E, Dampier W, Ertel A, Yu Z, Saria EA, Papanikolaou A, Li Z, Wang C, Addya S, Lisanti MP, Fortina P, Cardiff RD, Tozeren A, Knudsen ES, Arnold A, Pestell RG.

Oncotarget. 2015 Apr 20;6(11):8525-38.

48.

The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module.

Chen K, Wu K, Jiao X, Wang L, Ju X, Wang M, Di Sante G, Xu S, Wang Q, Li K, Sun X, Xu C, Li Z, Casimiro MC, Ertel A, Addya S, McCue PA, Lisanti MP, Wang C, Davis RJ, Mardon G, Pestell RG.

Cancer Res. 2015 May 15;75(10):1992-2004. doi: 10.1158/0008-5472.CAN-14-0611. Epub 2015 Mar 13.

49.

Antibiotics for cancer therapy.

Pestell RG, Rizvanov AA.

Oncotarget. 2015 Feb 20;6(5):2587-8. No abstract available.

50.

Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction.

Lamb R, Harrison H, Smith DL, Townsend PA, Jackson T, Ozsvari B, Martinez-Outschoorn UE, Pestell RG, Howell A, Lisanti MP, Sotgia F.

Oncotarget. 2015 Mar 10;6(7):4585-601.

Supplemental Content

Loading ...
Support Center